Pulmonx Corporation
Financials
Valuation Metrics
Pulmonx Corporation's Market Cap is $84M. At end of 2025 it was $92M. Ranked #3086 of 3,121 in US market (top 99%), #1432 of 1,463 on NASDAQ (top 98%), #200 of 205 in Health Care Equipment & Services (top 98%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $84M | US#3,086/3,121 Sec#200/205 |
| Revenue | $87M | US#2,723/3,121 Sec#187/205 |
| Net Income | $-48M | US—/3,121 Sec—/205 |
| Total Assets | $115M | US#3,058/3,121 Sec#200/205 |
| Net Assets | $39M | US#2,877/3,121 Sec#186/205 |
| Employees | 296 | US#2,423/3,121 Sec#166/205 |
| Value | ||
| P/B | 2.13x | US#1,329/3,121 Sec#65/205 |
| P/S | 0.96x | US#672/3,121 Sec#46/205 |
| FCF Yield | -36.67% | US—/3,121 Sec—/205 |
| Profitability | ||
| ROE | -122.76% | US#2,811/3,121 Sec#184/205 |
| ROA | -41.94% | US#2,956/3,121 Sec#196/205 |
| Op. Margin | -52.96% | US#2,686/3,121 Sec#182/205 |
| Revenue Growth | -3.43% | US#2,429/3,121 Sec#180/205 |
| Financial Health | ||
| Debt Ratio | 192.71% | US#1,756/3,121 Sec#150/205 |
| Total Debt | $56M | US#2,591/3,121 Sec#153/205 |
| FCF | $-31M | US#2,471/3,121 Sec#170/205 |
| Cash | $56M | US#2,544/3,121 Sec#160/205 |
| Current Ratio | 4.32x | US#545/3,121 Sec#51/205 |
| Performance | ||
| 1Y Return | 27.74% | US#969/3,121 Sec#76/205 |
| 1M Return | -12.39% | US#2,657/3,121 Sec#181/205 |
| From 52W High | -31.49% | US#2,136/3,121 Sec#143/205 |
| 1Y MDD | -55.00% | US#2,633/3,121 Sec#157/205 |
| Trading | ||
| Volume | 263,997 shares | US#2,490/3,121 Sec#176/205 |
| Trading Value | $525354.00 | US#3,068/3,121 Sec#201/205 |
| Per Share | ||
| EPS | $-1.14 | US—/3,121 Sec—/205 |
| BPS | $0.93 | US#2,711/3,121 Sec#182/205 |
Company Info
Pulmonx Corporation is a biomedical technology firm dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases. Its primary offering, the Zephyr Endobronchial Valve, is specifically engineered to treat bronchoscopic hyperinflation in adults afflicted with severe emphysema. Complementing its therapeutic solutions, the company also provides the Chartis Pulmonary Assessment System. This system features a specialized balloon catheter and console, fitted with flow and pressure sensors, which is instrumental in evaluating the presence of collateral ventilation in patients. Additionally, Pulmonx offers the StratX Lung Analysis Platform, a cloud-based service that conducts quantitative computed tomography (CT) analysis. This platform delivers vital data concerning emphysema destruction, fissure completeness, and lobar volume, thereby aiding clinicians in accurately identifying the most suitable target lobes for treatment with Zephyr Valves. Pulmonx serves emphysema patients across a broad international footprint, encompassing the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. The company, which changed its name from Pulmonx to Pulmonx Corporation in December 2013, was originally incorporated in 1995 and maintains its corporate headquarters in Redwood City, California.